GOLD 2019 y GesEPOC 2017: What do they contribute in our COPD patients?

05 Aug 2021
Respiratory conditions
  • COPD
Type of resource
Abstract
Conference
Dublin 2021
Author(s)
Sílvia Álvarez, GRAP, Spain
Clinical Research Results AimsTo know the COPD patient profile according to both GesEPOC 2017 and GOLD 2019 guidelinesTo determinate de type of risk according to both guidelinesMethodAn observational transversal multicentric study in 7 PC centres. Patients included were between 35-85 years old with COPD diagnose made by spirometry (FEV1/FVC post-bronchodilator <0,7). Informed consent was collected.ResultsWere included 620 patients. Average age of 68 years old (SD 9,5). 77,2% men. 43.8% current smokers. FEV1 post-bronchodilator average 61,9% (SD11,44). GOLD classification: 51,1% A, 26,8% B, 6,6% C and 15,5% D. GesEPOC classification: Low risk 59%.38,5% no exacerbations with emphysema, 21,3% no exacerbation with chronic bronchitis, 8,1% exacerbator with emphysema, 6,3% chronic bronchitis with emphysema and 25,8% ACO phenotype. 8% had at least one serious exacerbation. 34,8% had inhaled corticosteroids as a treatment. 20,6% were without treatment and from these 78ç5 were GOLD A and 89,8% had low risk.ConclusionsGOLD A and B represents more tan half of the total of the patients.According to GesEPOC guideline the predominant patients are low risk and no exacerbator phenotypeThere is a high proportion of ACO phenotype that matches with literature.The great majority of patients not receiving treatment were GOLD A and low risk Implementation Science/Service Development Research Ideas on Respiratory Conditions and Tobacco Dependency Abstract Declaration of Interest We do not have conflict of interest. References and Clinical Trial Registry Information